



(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 31/555 (2006.01)
A61P 35/00 (2006.01) A61K 38/00 (2006.01)
A61K 31/337 (2006.01)

(21) International Application Number:

PCT/US2022/027142

(22) International Filing Date:

29 April 2022 (29.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/182,519 30 April 2021 (30.04.2021) US
63/193,381 26 May 2021 (26.05.2021) US
63/313,882 25 February 2022 (25.02.2022) US

(71) Applicant: PURETECH LYT, INC. [US/US]; 6 Tide Street, Suite 400, Boston, Massachusetts 02210 (US).

(72) Inventors: FILIPOVIC, Aleksandra; 6 Tide Street, Suite 400, Boston, Massachusetts 02210 (US). ELENKO, Eric; 6 Tide Street, Suite 400, Boston, Massachusetts 02210 (US). BOLEN, Joseph; 6 Tide Street, Suite 400, Boston, Massachusetts 02210 (US).

(74) Agent: DAVIS, J. Wendy et al.; McDermott Will & Emery LLP, 500 North Capitol Street, NW, Washington, District of Columbia 20001-1531 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMBINATION OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS FOR USE IN CANCER THERAPY

Fig. 1A Survival of mPA6115





Fig. 1B Survival of mPA6115



(57) Abstract: Disclosed herein are combined therapies for treating solid tumors (e.g., pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), cholangiocarcinoma (CAA), renal cell carcinoma (RCC), urothelial, head and neck, breast cancer, lung cancer, or other gastrointestinal solid tumors), comprising an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, for example, gemcitabine, paclitaxel, or a combination thereof.